FGFBP2 - fibroblast growth factor binding protein 2 Gene

Also Known as KSP37; HBP17RP

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 83888

About FGFBP2

Cytogenetic location: 4p15.32 Genomic coordinates (GRCh38): 4:15,960,245-15,963,175 (from NCBI)

This gene has 2 transcripts (splice variants), 152 orthologues and 2 paralogues. Biased expression in bone marrow (RPKM 17.7), spleen (RPKM 6.7) and 7 other tissues.

Summary

This gene encodes a member of the Fibroblast Growth Factor binding protein family. The encoded protein is a serum protein that is selectively secreted by cytotoxic lymphocytes and may be involved in cytotoxic lymphocyte-mediated immunity. An increase in the amount of gene product may be associated with atopic asthma and mild extrinsic asthma.[provided by RefSeq Staff, Oct 2008]

FGFBP2 Products (1)

mRNA Protein Name
NM_031950.4 NP_114156.1 fibroblast growth factor-binding protein 2 precursor

Gene Ontology

  • Molecular Function
Molecular Function GO Annotation Evidence Verweise Source
enables protein binding IPI
IPI: Inferred from physical interaction
32296183 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

FGFBP2 Protein Structure

FGF-BP1

FGF-BP1: FGF binding protein 1 (FGF-BP1) (1 - 223)

  • 0
  • 100
  • 200
  • 223 a.a.
Protein Preferred Names Protein Names

fibroblast growth factor-binding protein 2

  • 37 kDa killer-specific secretory protein

Recombinant FGFBP2 Proteins

Art. -Nr. Produktname Accession Reinheit
HY-P77433 FGFBP2 Protein, Human (sf9, His) Q9BYJ0 (Q20-G223) ≥ 90%, as determined by reducing SDS-PAGE.

Related Diseases

Diseases Alias
Cervical Adenosquamous Carcinoma

  • Adenosquamous Carcinoma Of Cervix

  • Adenosquamous Cell Carcinoma Of The Cervix Uteri
Asthma

  • Chronic Obstructive Asthma

  • Asthma, Diminished Response To Antileukotriene Treatment In

  • Bronchial Hyperreactivity

  • Asthma, Susceptibility To

  • Asthma, Bronchial

  • Asthma, Protection Against

  • Asthma, Nocturnal, Susceptibility To

  • Nocturnal Asthma

  • Asthma-Related Traits

  • Asthma-Related Traits, Susceptibility To

  • Asthma, Nocturnal

  • Chronic Obstructive Asthma With Acute Exacerbation

  • Chronic Obstructive Asthma With Status Asthmaticus

  • Exercise Induced Asthma

  • Exercise-Induced Asthma

  • Bronchial Asthma

  • Asthma, Exercise-Induced

  • Idiosyncratic Asthma

  • Unspecified Asthma With Acute Exacerbation

  • Asthma, Unspecified, With Stated Status Asthmaticus

  • Status Asthmaticus Nos

  • Acute Severe Asthma

  • Acute Severe Bronchial Asthma

  • Status Asthma

  • Status Post Asthmaticus
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Pre-clinical Phase

Pre-clinical Phase

Bioactive Molecules (1)
Art. -Nr. Produktname
Wirkung
Reinheit
Rare Diseases
HY-RS04909 FGFBP2 Human Pre-designed siRNA Set A Pre-designed Set / Unkown